{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041305","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.670266+00:00","generated_at":"2026-06-11T17:52:42.056458+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Kezar Life Sciences Q2 net loss $24.3M; cash $236.6M; clinical trials advancing","bullets":["Net loss of $24.3M ($0.34 per share) vs $16.2M ($0.25) in Q2 2022.","Cash equivalents and marketable securities $236.6M at June 30, 2023, down from $276.6M at Dec 31, 2022.","R&D expenses rose to $21.0M from $11.3M year-over-year, driven by zetomipzomib and KZR-261 programs.","PALIZADE Phase 2b (lupus nephritis) and PORTOLA Phase 2a (autoimmune hepatitis) open for enrollment; KZR-261 dose escalation continues."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041305","json":"https://secwatch.observer/filing/0000950170-23-041305.json","markdown":"https://secwatch.observer/filing/0000950170-23-041305.md","text":"https://secwatch.observer/filing/0000950170-23-041305.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023041305/0000950170-23-041305-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023041305/kzr-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:52:42.056458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67fb182e8f862e42cf6e22b7ef770d924a1ea5bf","claim":"Kezar Life Sciences, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 10, 2023, Kezar Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023041305/0000950170-23-041305-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}